A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location

被引:21
作者
Woo, Peter [1 ]
Ho, Jason [2 ]
Lam, Sandy [1 ]
Ma, Eric [1 ]
Chan, Danny [3 ]
Wong, Wai-Kei [4 ]
Mak, Calvin [5 ]
Lee, Michael [6 ]
Wong, Sui-To [2 ]
Chan, Kwong-Yau [1 ]
Poon, Wai-Sang [3 ]
机构
[1] Kwong Wah Hosp, Dept Neurosurg, Hong Kong, Hong Kong, Peoples R China
[2] Tuen Mun Hosp, Dept Neurosurg, Hong Kong, Hong Kong, Peoples R China
[3] Prince Wales Hosp, Dept Surg, Div Neurosurg, Hong Kong, Hong Kong, Peoples R China
[4] Princess Margaret Hosp, Dept Neurosurg, Hong Kong, Hong Kong, Peoples R China
[5] Queen Elizabeth Hosp, Dept Neurosurg, Hong Kong, Hong Kong, Peoples R China
[6] Pamela Youde Nethersole Eastern Hosp, Dept Neurosurg, Hong Kong, Hong Kong, Peoples R China
关键词
Glioblastoma; Nomogram; Overall survival; Prognosis; Recursive partitioning analysis; Temozolomide; RECURSIVE PARTITIONING ANALYSIS; NEWLY-DIAGNOSED GLIOBLASTOMA; PROGNOSTIC-FACTORS; MALIGNANT GLIOMA; RESPONSE ASSESSMENT; MULTIFORME; RADIOTHERAPY; VALIDATION; NOMOGRAMS; CLASSIFICATION;
D O I
10.1016/j.wneu.2018.04.059
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
OBJECTIVE: Several survival prediction models for patients with glioblastoma have been proposed, but none is widely used. This study aims to identify the predictors of overall survival (OS) and to conduct an independent comparative analysis of 5 prediction models. METHODS: Multi-institutional data from 159 patients with newly diagnosed glioblastoma who received adjuvant temozolomide concomitant chemoradiotherapy (CCRT) were collected. OS was assessed by Cox proportional hazards regression and adjusted for known prognostic factors. An independent CCRT patient cohort was used to externally validate the 1) RTOG (Radiation Therapy Oncology Group) recursive partitioning analysis (RPA) model, 2) Yang RPA model, and 3) Wee RPA model, Chai-chana model, and the RTOG nomogram model. The predictive accuracy for each model at 12-month survival was determined by concordance indices. Calibration plots were performed to ascertain model prediction precision. RESULTS: The median OS for patients who received CCRT was 19.0 months compared with 12.7 months for those who did not (P < 0.001). Independent predictors were: 1) subventricular zone II tumors (hazard ratio [HR], 1.6; 95% confidence interval [CI], 1.0-2.5); 2) methylguanine methyltransferase promoter methylation (HR, 0.36; 95% CI, 0.2-0.6); and 3) extent of resection of >85% (HR, 0.59; 95% CI, 0.4-0.9). For 12-month OS prediction, the RTOG nomogram model was superior to the RPA models with a c-index of 0.70. Calibration plots for 12-month survival showed that none of the models was precise, but the RTOG nomogram performed relatively better. CONCLUSIONS: The RTOG nomogram best predicted 12-month OS. Methylguanine methyltransferase promoter methylation status, subventricular zone tumor location, and volumetric extent of resection should be considered when constructing prediction models.
引用
收藏
页码:E375 / E385
页数:11
相关论文
共 66 条
  • [1] Prognosis and prognostic research: validating a prognostic model
    Altman, Douglas G.
    Vergouwe, Yvonne
    Royston, Patrick
    Moons, Karel G. M.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2009, 338 : 1432 - 1435
  • [2] Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era A Correlative Analysis Based on NRG Oncology RTOG 0525
    Bell, Erica Hlavin
    Pugh, Stephanie L.
    McElroy, Joseph P.
    Gilbert, Mark R.
    Mehta, Minesh
    Klimowicz, Alexander C.
    Magliocco, Anthony
    Bredel, Markus
    Robe, Pierre
    Grosu, Anca-L.
    Stupp, Roger
    Curran, Walter, Jr.
    Becker, Aline P.
    Salavaggione, Andrea L.
    Barnholtz-Sloan, Jill S.
    Aldape, Kenneth
    Blumenthal, Deborah T.
    Brown, Paul D.
    Glass, Jon
    Souhami, Luis
    Lee, Jeffrey
    Brachman, David
    Flickinger, John
    Won, Minhee
    Chakravarti, Arnab
    [J]. JAMA ONCOLOGY, 2017, 3 (06) : 784 - 792
  • [3] Association of the Extent of Resection With Survival in Glioblastoma A Systematic Review and Meta-analysis
    Brown, Timothy J.
    Brennan, Matthew C.
    Li, Michael
    Church, Ephraim W.
    Brandmeir, Nicholas J.
    Rakszawski, Kevin L.
    Patel, Akshal S.
    Rizk, Elias B.
    Suki, Dima
    Sawaya, Raymond
    Glantz, Michael
    [J]. JAMA ONCOLOGY, 2016, 2 (11) : 1460 - 1469
  • [4] An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation
    Candido dos Reis, Francisco J.
    Wishart, Gordon C.
    Dicks, Ed M.
    Greenberg, David
    Rashbass, Jem
    Schmidt, Marjanka K.
    van den Broek, Alexandra J.
    Ellis, Ian O.
    Green, Andrew
    Rakha, Emad
    Maishman, Tom
    Eccles, Diana M.
    Pharoah, Paul D. P.
    [J]. BREAST CANCER RESEARCH, 2017, 19
  • [5] A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme Clinical article
    Chaichana, Kaisorn
    Parker, Scott
    Olivi, Alessandro
    Quinones-Hinojosa, Alfredo
    [J]. JOURNAL OF NEUROSURGERY, 2010, 112 (05) : 997 - 1004
  • [6] Relationship of glioblastoma multiforme to the lateral ventricles predicts survival following tumor resection
    Chaichana, Kaisorn L.
    McGirt, Matthew J.
    Frazier, James
    Attenello, Frank
    Guerrero-Cazares, Hugo
    Quinones-Hinojosa, Alfredo
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2008, 89 (02) : 219 - 224
  • [7] Multi-institutional validation of a preoperative scoring system which predicts survival for patients with glioblastoma
    Chaichana, Kaisorn L.
    Pendleton, Courtney
    Chambless, Lola
    Camara-Quintana, Joaquin
    Nathan, Jay K.
    Hassam-Malani, Laila
    Li, Gordon
    Harsh, Griffith R.
    Thompson, Reid C.
    Lim, Michael
    Quinones-Hinojos, Alfredo
    [J]. JOURNAL OF CLINICAL NEUROSCIENCE, 2013, 20 (10) : 1422 - 1426
  • [8] RECURSIVE PARTITIONING ANALYSIS OF PROGNOSTIC FACTORS IN 3 RADIATION-THERAPY ONCOLOGY GROUP MALIGNANT GLIOMA TRIALS
    CURRAN, WJ
    SCOTT, CB
    HORTON, J
    NELSON, JS
    WEINSTEIN, AS
    FISCHBACH, AJ
    CHANG, CH
    ROTMAN, M
    ASBELL, SO
    KRISCH, RE
    NELSON, DF
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (09) : 704 - 710
  • [9] Has the survival of patients with glioblastoma changed over the years?
    deSouza, R. M.
    Shaweis, H.
    Han, C.
    Sivasubramiam, V.
    Brazil, L.
    Beaney, R.
    Sadler, G.
    Al-Sarraj, S.
    Hampton, T.
    Logan, J.
    Hurwitz, V.
    Bhangoo, R.
    Gullan, R.
    Ashkan, K.
    [J]. BRITISH JOURNAL OF CANCER, 2016, 114 (02) : 146 - 150
  • [10] Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
    Ellingson, Benjamin M.
    Wen, Patrick Y.
    Cloughesy, Timothy F.
    [J]. NEUROTHERAPEUTICS, 2017, 14 (02) : 307 - 320